SavedAdd your journal

Journals / Meandros Medical And Dental Journal / 2020 / Cilt: 21 - Sayı: 1

MRONJ Maksiller Sinüs Kalınlığını ve Sinüs Volümünü Etkiler mi?

Does Medication-related Osteonecrosis of the Jaw Affect Maxillary Sinus Volume and Mucosal Thickness?

CANAY YILMAZ ASAN
ZEYNEP BURÇİN GÖNEN
Emine Fulya AKKOYUN
Erdem KILIÇ
Alper ALKAN
Pages
12–18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Gruplar arasındaki sinüs volümleri ve mukoza kalınlaşmaları istatistiksel olarak karşılaştırıldı.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amaç: Bifosfonatlar (BPs), antirezorptif etkilerinden dolayı sıklıkla tercih edilen ilaçlardır.
📊
Key Findings & Data:Gereç ve Yöntemler: Bu çalışmada, 27 hastadaki 54 maksiller sinüse ait konik ışınlı bilgisayarlı tomografi görüntüleri değerlendirildi.
💡
Conclusion & Impact:Gruplar arasındaki sinüs volümleri ve mukoza kalınlaşmaları istatistiksel olarak karşılaştırıldı.
🔬Design:Research Article
📍Scope:27 hasta
⚙️Variables:Domain Parameters

Abstract

Amaç: Bifosfonatlar (BPs), antirezorptif etkilerinden dolayı sıklıkla tercih edilen ilaçlardır. Çenelerin ilaçlarla ilişkili osteonekrozu (MRONJ), BP'lerin bir komplikasyonudur. Bu çalışmanın amacı, MRONJ hastalarının maksiller sinüs volümleri ve mukozal kalınlıklarının, sağlıklı bireylerle karşılaştırılmasıdır. Gereç ve Yöntemler: Bu çalışmada, 27 hastadaki 54 maksiller sinüse ait konik ışınlı bilgisayarlı tomografi görüntüleri değerlendirildi. Çalışmaya dahil edilen hastalar üç gruba ayrıldı. Çalışma grubu olarak belirlenen grup 1 (n=8) maksillada MRONJ gelişen hastalardan; grup 2 (n=9) BP kullanan ancak maksillada MRONJ gelişmeyen hastalardan oluşurken; kontrol grubu olan grup 3 (n=10) sağlıklı bireylerden oluşmakta idi. Gruplar arasındaki sinüs volümleri ve mukoza kalınlaşmaları istatistiksel olarak karşılaştırıldı.

Özet

Objective: Bisphosphonates (BPs) are commonly prescribed drugs because of their antiresorptive effects. However, BPs may cause medication-related osteonecrosis of the jaw (MRONJ). This study aimed to compare the maxillary sinus volumes and mucosal thickening of patients with MRONJ and healthy patients.Materials and Methods: This retrospective cohort study evaluated cone-beam computed tomography images of 54 maxillary sinuses in 27 patients. Patients were divided into three groups: group 1 (n=8), patients with maxillary MRONJ; group 2 (n=9), patients treated with BPs and had no maxillary osteonecrosis (study groups); and group 3 (n=10), healthy individuals (control group). Maxillary sinus volumes and mucosal thickening were compared among the groups.Results: No statistically significant difference in maxillary sinus volumes was found among the groups (p=0.153). The mean mucosal thickening was 5.920±5.94 mm in group 1, 1.718±2.58 in group 2 and 1.265±0.83 in group 3. Mucosal thickening was prominent significantly in Group 1 (p=0.001). Conclusion: BPs can affect oral soft tissues as well as hard tissues. The study results showed significant changes in maxillary sinus mucosal thickening in patients with maxillary MRONJ.

🔖

Cite This Article

ASAN, C. Y., GÖNEN, Z. B., AKKOYUN, E. F., KILIÇ, E., ALKAN, A. (2020). MRONJ Maksiller Sinüs Kalınlığını ve Sinüs Volümünü Etkiler mi?. Meandros Medical And Dental Journal, Cilt: 21 - Sayı: 1, 12–18. https://ajindex.com/articles/341437

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67: 2-12
  2. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297-304
  3. Delmas PD, Meunier PJ. The management of Paget’s disease of bone. N Engl J Med 1997; 336: 558-66
  4. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977-86
  5. Maurer P, Sandulescu T, Kriwalsky MS, Rashad A, Hollstein S, Stricker I, et al. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. Int J Oral Maxillofac Surg 2011; 40: 285-91
  6. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-7
  7. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-3
  8. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-75
  9. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34
  10. Voss PJ, Vargas Soto G, Schmelzeisen R, Izumi K, Stricker A, Bittermann G, et al. Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla. Head Face Med 2016; 12: 3
  11. Mast G, Otto S, Mücke T, Schreyer C, Bissinger O, Kolk A, et al. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J Craniomaxillofac Surg 2012; 40: 568-71
  12. Gallego L, Junquera L, Pelaz A, García-Consuegra L, AlvarezArenal A, Costilla S. Sinus mucosal thickening in bisphosphonaterelated osteonecrosis of the jaws